

TRAVIS P. REMARCHUK, PH.D.
Denali Therapeutics, Inc.
161 Oyster Point Blvd., South San Francisco, CA 94080
remarchuk@dnli.com / m. (415) 370-0359

Professional Experience

12/18-Present Staff Scientist, Process Research & Development / CMC, Denali Therapeutics, Inc.
04/16-12/18 Principal Scientist, Process Research & Development / CMC, Denali Therapeutics, Inc., South San Francisco, CA
05/15-03/16 Senior Scientist, Small Molecule Process Chemistry, Genentech (A member of the Roche group), South San Francisco, CA
2006–2015 Scientist, Small Molecule Process Chemistry, Genentech (A member of the Roche group), South San Francisco, CA
1995–1998 Research Associate, Process Chemistry, Agouron Pharmaceuticals, Inc. San Diego, CA
1994-1995 Research Associate, Discovery Chemistry, La Jolla Pharmaceuticals, Inc., San Diego, CA

Education

2003–2006 Postdoctoral Research, Harvard University, Department of Chemistry and Chemical Biology, Cambridge, MA. Advisor: Professor E. J. Corey (Nobel Laureate 1990)
1998-2003 Ph.D. Organic Chemistry, University of California Irvine, Irvine, CA
Advisor: Professor Larry E. Overman (Distinguished Professor)
1989-1994: B.Sc. in Chemistry, University of Saskatchewan, SK, Canada.
Advisor: Professor Marek Majewski

Research Publications

- 1. Manufacture of the PI3k- β sparing Inhibitor Taselisib. Part 1: Early-Stage Development Routes to the Bromobenzoxazapine Core;** *Remarchuk, T.*; Angelaud, R.; Askin, D.; Kumar, A.; Thompson, A. S.; Cheng, H.; Reichwein, J. F.; Chen, Y.; St-Jean, F. *Org. Process Res. Dev.* **2019**, *24*, ASAP.
- 2. Manufacture of the PI3k- β sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process;** St-Jean, F.; *Remarchuk, T.*; Angelaud, R.; Carrera, D.; Beaudry, D.; Malhotra, S.; McClory, A.; Kumar, A.; Ohlenbusch, G.; Schuster, A. M.; Gosselin, F. *Org. Process Res. Dev.* **2019**, *24*, ASAP.
- 3. Stereodivergent Synthesis of Novel Chiral C2-Symmetric Bis-Trifluoromethyl-2-oxazolidinones;** Remarchuk, T.; Corey, E. J. *Tetrahedron Letters*, **2018**, *59*, 2256–2259.
- 4. Highly Efficient Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib;** Han, C.; Savage, S.; Al-Sayah, M.; Yajima, H.; *Remarchuk, T.*; Reents, R.; Wirz, B.; Iding, H.; Bachmann, S.; Fantasia, S. M.; Scalone, M.; Gosselin, F. *Org. Lett.* **2017**, *19*, 4806–4809.
- 5. Practical Approaches to Large-Scale Heterocyclic Synthesis;** Featured in *Pharmaceutical Technology*, December 1st, 2014 (Interview by Cynthia Challener).
- 6. Synthesis of Akt Inhibitor Ipatasertib. Part 2. Total Synthesis and First Kilogram Scale-up;** *Remarchuk, T.* St-Jean, F.; Carrera, D.; Savage, S.; Yajima, H.; Wong, B.; Babu, S.; Deese, A.; Stults, J.; Dong, M. W.; Askin, D.; Lane, J. W.; Spencer, K. L. *Org. Process Res. Dev.* **2014**, *18*, 1652–1666.

7. **Synthesis of Akt Inhibitor Ipatasertib. Part 1. Route Scouting and Early Process Development of a Challenging Cyclopentylpyrimidine Intermediate;** Lane, J. W.; Spencer, K. L.; Shakya, S. R.; Kallan, N. C.; Stengel, P. J.; *Remarchuk, T. Org. Process Res. Dev.* **2014**, *18*, 1641–1651.
8. **An Efficient Catalytic Asymmetric Synthesis of a β -Amino Acid on Multi-Kilogram Scale;** *Remarchuk, T. P.*; Babu, S.; Stults, J.; Zanotti-Gerosa, A.; Roseblade, S.; Yang, S.; Huang, P.; Sha, C.; Wang, Y. *Org. Process Res. Dev.* **2014**, *18*, 135–141. Highlighted in *Synfacts*, **2014**.
9. **Byproducts of Commonly Used Coupling Reagents: Origin, Toxicological Evaluation and Methods for Determination;** Wigman, L.; *Remarchuk, T.*; Gomez, S. R.; Kumar, A.; Dong, M. W.; Medley, C. D.; Chetwyn, N. P. *Am. Pharm. Rev.* (2014).
10. **Catalysis of Enantioselective [2+1]-Cycloaddition Reactions of Ethyl Diazoacetate and Terminal Acetylenes Using Mixed-Ligand Complexes of the Series $Rh_2(RCO)_2(L^*_{4n})$. Stereochemical Heuristics for Ligand Exchange and Catalyst Synthesis;** Lou, Y.; *Remarchuk, T. P.*; Corey, E. J. *J. Am. Chem. Soc.* **2005**, *127*, 14223–14230.
11. **Catalytic Asymmetric Intramolecular Aminopalladation: Enantioselective Synthesis of Vinyl-Substituted 2-Oxazolidinones, 2-Imidazolidinones and 2-Pyrrolidinones;** Overman, L. E.; *Remarchuk, T. J. Am. Chem. Soc.* **2002**, *124*, 12–13.
12. **A Synthesis of the HIV-Protease Inhibitor Nelfinavir from D-Tartaric Acid;** Albizati, K. F.; Babu, S.; Birchler, A.; Busse, J. K.; Fugett, M.; Grubbs, A.; Haddach, A.; Pagan, M.; Potts, B.; *Remarchuk, T.*; Rieger, D.; Rodriguez, R.; Shanley, J.; Tibbetts, T.; Whitten, K.; Borer, B. C. *Tet. Lett.* **2001**, *42*, 6481–6485.